亚叶酸使肠球菌对甲氧苄啶-磺胺甲恶唑的体外药敏性发生逆转。
Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid.
作者信息
Zervos M J, Schaberg D R
出版信息
Antimicrob Agents Chemother. 1985 Sep;28(3):446-8. doi: 10.1128/AAC.28.3.446.
Abstract
The in vitro susceptibilities of 21 clinical isolates of Streptococcus faecalis to trimethoprim (TMP) in combination with sulfamethoxazole (SMX) was evaluated in Mueller-Hinton broth (MHB) in the presence and absence of folinic acid as well as in urine. The mean MIC and MBC in MHB, expressed as the TMP concentration, was 0.13 and 0.32 micrograms of TMP-SMX per ml, respectively. In MHB supplemented with folinic acid, the mean MIC and MBC was 3.3 and 5.5 micrograms of TMP-SMX per ml, respectively. In urine the mean MIC of TMP-SMX for these isolates was 8.1 micrograms/ml (range, 1.6 to 50 micrograms/ml). All isolates were inhibited by less than 0.01 micrograms of TMP-SMX per ml when methotrexate was added to the urine.
摘要
在含有和不含亚叶酸的穆勒-欣顿肉汤（MHB）以及尿液中，评估了21株粪肠球菌临床分离株对甲氧苄啶（TMP）与磺胺甲恶唑（SMX）联合用药的体外敏感性。在MHB中，以TMP浓度表示的平均MIC和MBC分别为每毫升0.13和0.32微克TMP-SMX。在添加亚叶酸的MHB中，平均MIC和MBC分别为每毫升3.3和5.5微克TMP-SMX。在尿液中，这些分离株的TMP-SMX平均MIC为8.1微克/毫升（范围为1.6至50微克/毫升）。当向尿液中添加甲氨蝶呤时，所有分离株均被每毫升低于0.01微克的TMP-SMX抑制。
相似文献
1
Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid.亚叶酸使肠球菌对甲氧苄啶-磺胺甲恶唑的体外药敏性发生逆转。
Antimicrob Agents Chemother. 1985 Sep;28(3):446-8. doi: 10.1128/AAC.28.3.446.
2
Susceptibility of enterococci to trimethoprim and trimethoprim-sulfamethoxazole.肠球菌对甲氧苄啶及复方新诺明的敏感性
Antimicrob Agents Chemother. 1985 Jan;27(1):71-5. doi: 10.1128/AAC.27.1.71.
3
Failure to demonstrate a consistent in vitro bactericidal effect of trimethoprim-sulfamethoxazole against enterococci.未能证明甲氧苄啶-磺胺甲恶唑对肠球菌具有持续的体外杀菌作用。
Antimicrob Agents Chemother. 1987 May;31(5):808-10. doi: 10.1128/AAC.31.5.808.
4
Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group.流感嗜血杆菌和肺炎链球菌对甲氧苄啶及甲氧苄啶-磺胺甲恶唑敏感性检测的解释标准和质量控制参数。抗菌药物敏感性检测OC组。
J Clin Microbiol. 1997 Jan;35(1):125-31. doi: 10.1128/jcm.35.1.125-131.1997.
5
Lack of activity of sulfamethoxazole and trimethoprim against anaerobic bacteria.磺胺甲恶唑和甲氧苄啶对厌氧菌缺乏活性。
Antimicrob Agents Chemother. 1974 Jul;6(1):93-7. doi: 10.1128/AAC.6.1.93.
6
Emergence of highly trimethoprim-sulfamethoxazole-resistant Shigella in a native American population: an epidemiologic study.美国原住民群体中对甲氧苄啶-磺胺甲恶唑高度耐药的志贺菌的出现：一项流行病学研究。
Am J Epidemiol. 1989 May;129(5):1042-51. doi: 10.1093/oxfordjournals.aje.a115208.
7
Combined activity of sulfamethoxazole, trimethoprim, and polymyxin B against gram-negative bacilli.磺胺甲恶唑、甲氧苄啶和多粘菌素B对革兰氏阴性杆菌的联合活性
Antimicrob Agents Chemother. 1974 Jul;6(1):84-92. doi: 10.1128/AAC.6.1.84.
8
Quality control of susceptibility tests with 5-micrograms trimethoprim disks.使用5微克甲氧苄啶纸片进行药敏试验的质量控制。
J Clin Microbiol. 1984 Oct;20(4):817-9. doi: 10.1128/jcm.20.4.817-819.1984.
9
Intravenous trimethoprim-sulfamethoxazole alone or combined with tobramycin for infections in cancer patients.
Am J Med Sci. 1980 Jan-Feb;279(1):4-13. doi: 10.1097/00000441-198001000-00001.
10
Serum and saliva concentrations of sulfamethoxazole and trimethoprim in adults and children: relation between saliva concentrations and in vitro activity against nasopharyngeal pathogens.
Scand J Infect Dis. 1983;15(1):107-13. doi: 10.3109/inf.1983.15.issue-1.18.
引用本文的文献
1
Replicative selfish genetic elements are driving rapid pathogenic adaptation of .复制性自私遗传元件正在推动……的快速致病性适应。 （原文句子不完整）
bioRxiv. 2025 Mar 16:2025.03.16.643550. doi: 10.1101/2025.03.16.643550.
2
Acquired Bacterial Resistance to Antibiotics and Resistance Genes: From Past to Future.获得性细菌对抗生素的耐药性及耐药基因：从过去到未来
Antibiotics (Basel). 2025 Feb 21;14(3):222. doi: 10.3390/antibiotics14030222.
3
Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: a review.抗菌耐药机制、遏制抗菌耐药的策略及下一代抗菌药物：综述
Front Pharmacol. 2024 Aug 16;15:1444781. doi: 10.3389/fphar.2024.1444781. eCollection 2024.
4
Linezolid in enterococcal urinary tract infection: a multicentre study.利奈唑胺治疗肠球菌尿路感染：一项多中心研究。
Eur J Clin Microbiol Infect Dis. 2024 Nov;43(11):2107-2115. doi: 10.1007/s10096-024-04923-7. Epub 2024 Aug 21.
5
Antimicrobial Susceptibility of Canine and Feline Urinary Tract Infection Pathogens Isolated from Animals with Clinical Signs in European Veterinary Practices during the Period 2013-2018.2013年至2018年期间，从欧洲兽医诊所出现临床症状的动物中分离出的犬猫泌尿道感染病原体的抗菌药敏性
Antibiotics (Basel). 2024 May 28;13(6):500. doi: 10.3390/antibiotics13060500.
6
Enterococci Isolated from One-Day-Old Chickens and Their Phenotypic Susceptibility to Antimicrobials in the Czech Republic.从捷克共和国一日龄雏鸡中分离出的肠球菌及其对抗菌药物的表型敏感性
Antibiotics (Basel). 2023 Sep 27;12(10):1487. doi: 10.3390/antibiotics12101487.
7
Bacterial resistance to antibacterial agents: Mechanisms, control strategies, and implications for global health.细菌对抗菌药物的耐药性：机制、控制策略及其对全球健康的影响。
Sci Total Environ. 2023 Feb 20;860:160461. doi: 10.1016/j.scitotenv.2022.160461. Epub 2022 Nov 23.
8
Using Functional Annotations to Study Pairwise Interactions in Urinary Tract Infection Communities.利用功能注释研究尿路感染群落中的成对相互作用。
Genes (Basel). 2021 Aug 6;12(8):1221. doi: 10.3390/genes12081221.
9
Assessment of Nitrofurantoin as an Experimental Intracanal Medicament in Endodontics.评估呋喃妥因作为牙髓腔内药物的实验研究。
Biomed Res Int. 2020 Feb 18;2020:2128473. doi: 10.1155/2020/2128473. eCollection 2020.
10
Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence.细菌的抗药性：机制、进化与持续。
J Mol Evol. 2020 Jan;88(1):26-40. doi: 10.1007/s00239-019-09914-3. Epub 2019 Oct 28.
本文引用的文献
1
Enterococci. Biologic and epidemiologic characteristics and in vitro susceptibility.肠球菌。生物学和流行病学特征以及体外药敏性。
Arch Intern Med. 1982 Oct 25;142(11):2006-9. doi: 10.1001/archinte.142.11.2006.
2
In-vitro activity of Sch 29482, MK 0787, ceftriaxone and seven other antimicrobials against 840 separate clinical isolates.
J Antimicrob Chemother. 1982 Feb;9 Suppl C:79-89. doi: 10.1093/jac/9.suppl_c.79.
3
Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center.肠球菌性心内膜炎。对纽约医院-康奈尔医学中心观察的38例患者的分析。
Arch Intern Med. 1970 Feb;125(2):258-64. doi: 10.1001/archinte.125.2.258.
4
Trimethoprim, a sulphonamide potentiator.甲氧苄啶，一种磺胺增效剂。
Br J Pharmacol Chemother. 1968 May;33(1):72-90. doi: 10.1111/j.1476-5381.1968.tb00475.x.
5
Reversal of the antimicrobial activity of trimethoprim by thymidine in commercially prepared media.在商业制备的培养基中，胸腺嘧啶核苷可逆转甲氧苄啶的抗菌活性。
Appl Microbiol. 1971 Nov;22(5):812-7. doi: 10.1128/am.22.5.812-817.1971.
6
Trimethoprim-sulfamethoxazole: in vitro microbiological aspects.甲氧苄啶-磺胺甲恶唑：体外微生物学方面
J Infect Dis. 1973 Nov;128:Suppl:442-62 p. doi: 10.1093/infdis/128.supplement_3.s442.
7
Susceptibility of enterococci to trimethoprim and trimethoprim-sulfamethoxazole.肠球菌对甲氧苄啶及复方新诺明的敏感性
Antimicrob Agents Chemother. 1985 Jan;27(1):71-5. doi: 10.1128/AAC.27.1.71.
Zotero 插件